Drug intelligence / Profile preview

PF-04764793

Development stage: Discontinued
Lead developer: Pfizer
Modality: Small Molecules
Administration: Inhalation

Overview

PF-04764793 is a dry powder small molecule compound developed by Pfizer as a potential inhaled treatment for asthma. The mechanism of action is not publicly defined. It was administered using a dry powder inhaler, with phase 1 trials completed in healthy volunteers and development subsequently discontinued at the phase 1 stage for asthma[3].

Other names: PF 4764793PF4764793PF-4764793PF 00241939PF00241939PF-00241939PF 241939PF241939PF-241939

Targets

PTGDR2 (Prostaglandin D2 receptor 2)

Beyond the preview

Go deeper on PF-04764793.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-04764793.

Explore the full profile